Clinical impact of lymphovascular invasion in pancreatic neuroendocrine tumors: A retrospective multicenter study

Clinical impact of lymphovascular invasion in pancreatic neuroendocrine tumors: A retrospective multicenter study - Clinical impact of lymphovascular invasion in pancreatic neuroendocrine tumors: A retrospective multicenter study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056360

Enrollment

800

Registered

2024-12-05

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The surgically resected pancreatic neuroendocrine tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent pancreatic resection and were pathologically diagnosed with pancreatic neuroendocrine tumors between January 1996 and December 2019.

Exclusion criteria

Exclusion criteria: Surgical resection of recurrence lesions only (e.g., liver metastases, lymph nodes). Surgical resection of metastatic lesions solely for the purpose of mass reduction or alleviation of hormone-producing symptoms. Cases in which differentiation from conventional pancreatic cancer is challenging in pathological diagnosis. Other cases deemed unsuitable for inclusion in this study by the principal investigator or co-investigators.

Design outcomes

Primary

Measure	Time frame
Clinicopathological characteristics of surgically resected non-functional pancreatic neuroendocrine tumors and insulinomas based on the lymphovascular invasion.	—

Countries

Japan

Contacts

Public ContactDaiki Yamashige

National Cancer Center Hospital Department of Hepatobiliary and Pancreatic Oncology

dyamashi@ncc.go.jp03-3542-2511

Outcome results